Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies
Glial-origin brain tumors, particularly glioblastomas (GBMs), are known for their devastating prognosis and are characterized by rapid progression and fatal outcomes. Despite advances in surgical resection, complete removal of the tumor remains unattainable, with residual cells driving recurrence th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/3/385 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850279656023916544 |
|---|---|
| author | Martina Bedeschi Elena Cavassi Antonino Romeo Anna Tesei |
| author_facet | Martina Bedeschi Elena Cavassi Antonino Romeo Anna Tesei |
| author_sort | Martina Bedeschi |
| collection | DOAJ |
| description | Glial-origin brain tumors, particularly glioblastomas (GBMs), are known for their devastating prognosis and are characterized by rapid progression and fatal outcomes. Despite advances in surgical resection, complete removal of the tumor remains unattainable, with residual cells driving recurrence that is resistant to conventional therapies. The GBM tumor microenviroment (TME) significantly impacts tumor progression and treatment response. In this review, we explore the emerging role of purinergic signaling, especially the P2X7 receptor (P2X7R). Due to its unique characteristics, it plays a key role in tumor progression and offers a potential therapeutic strategy for GBM through TME modulation. We discuss also the emerging role of the P2X4 receptor (P2X4R) as a promising therapeutic target. Overall, targeting purinergic signaling offers a potential approach to overcoming current GBM treatment limitations. |
| format | Article |
| id | doaj-art-875972a26b4c47a6bc2cd31704d24d5d |
| institution | OA Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-875972a26b4c47a6bc2cd31704d24d5d2025-08-20T01:49:01ZengMDPI AGPharmaceuticals1424-82472025-03-0118338510.3390/ph18030385Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel TherapiesMartina Bedeschi0Elena Cavassi1Antonino Romeo2Anna Tesei3Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, ItalyBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, ItalyRadiation Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, ItalyBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, ItalyGlial-origin brain tumors, particularly glioblastomas (GBMs), are known for their devastating prognosis and are characterized by rapid progression and fatal outcomes. Despite advances in surgical resection, complete removal of the tumor remains unattainable, with residual cells driving recurrence that is resistant to conventional therapies. The GBM tumor microenviroment (TME) significantly impacts tumor progression and treatment response. In this review, we explore the emerging role of purinergic signaling, especially the P2X7 receptor (P2X7R). Due to its unique characteristics, it plays a key role in tumor progression and offers a potential therapeutic strategy for GBM through TME modulation. We discuss also the emerging role of the P2X4 receptor (P2X4R) as a promising therapeutic target. Overall, targeting purinergic signaling offers a potential approach to overcoming current GBM treatment limitations.https://www.mdpi.com/1424-8247/18/3/385purinergic receptorsglioblastomatumor microenvironmentP2X7RP2X4Rpurinergic antagonists |
| spellingShingle | Martina Bedeschi Elena Cavassi Antonino Romeo Anna Tesei Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies Pharmaceuticals purinergic receptors glioblastoma tumor microenvironment P2X7R P2X4R purinergic antagonists |
| title | Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies |
| title_full | Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies |
| title_fullStr | Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies |
| title_full_unstemmed | Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies |
| title_short | Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies |
| title_sort | glioblastoma tumor microenvironment and purinergic signaling implications for novel therapies |
| topic | purinergic receptors glioblastoma tumor microenvironment P2X7R P2X4R purinergic antagonists |
| url | https://www.mdpi.com/1424-8247/18/3/385 |
| work_keys_str_mv | AT martinabedeschi glioblastomatumormicroenvironmentandpurinergicsignalingimplicationsfornoveltherapies AT elenacavassi glioblastomatumormicroenvironmentandpurinergicsignalingimplicationsfornoveltherapies AT antoninoromeo glioblastomatumormicroenvironmentandpurinergicsignalingimplicationsfornoveltherapies AT annatesei glioblastomatumormicroenvironmentandpurinergicsignalingimplicationsfornoveltherapies |